Literature DB >> 12603343

Disposition kinetics of ketotifen from liposomal dry powder for inhalation in rat lung.

Mayank Joshi1, Ambikanandan Misra.   

Abstract

1. The aim of the present study was to understand the benefit of liposomal dry powder for inhalation (LDPI) of ketotifen fumarate (KF) over plain drug dry powder for inhalation as a pulmonary targetted drug-delivery system. 2. The KF liposomes, composed of egg phosphatidyl choline and cholesterol, were prepared by the lipid film hydration technique. The liposomal dispersion was freeze dried and formulated to a dry powder for inhalation. Values of 89.0-65.3% drug entrapment of freeze-dried liposomes were estimated in prepared batches. 3. Rehydrated KF liposomes formed by the hydration of LDPI or the plain KF solution was delivered to rat lungs by intratracheal instillation. Simultaneous monitoring of drug levels in the bronchoalveolar lavage and lung tissue enabled assessment of pulmonary drug disposition. 4. Cumulative drug levels in lung tissue after intratracheal administration revealed that with liposomes targetting factors were between 1.36 and 1.54. The maximal drug concentration in lung homogenate for LDPI was 42.0 micro g compared with 73.6 micro g for plain drug solution. 5. Similarly, the time to reach maximum drug concentration in the lung homogenate for liposomal dry powder was 9-12 h compared with 3 h for plain drug. 6. Hence, the use of LDPI of KF was found to provide desired drug levels in the lung for a long time and thereby increased pulmonary targetting 7. This is expected to enhance the therapeutic index of the drug and probably reduce the dose administered and the cost of therapy.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12603343     DOI: 10.1046/j.1440-1681.2003.03813.x

Source DB:  PubMed          Journal:  Clin Exp Pharmacol Physiol        ISSN: 0305-1870            Impact factor:   2.557


  7 in total

Review 1.  Therapeutic liposomal dry powder inhalation aerosols for targeted lung delivery.

Authors:  Lauren Willis; Don Hayes; Heidi M Mansour
Journal:  Lung       Date:  2012-01-25       Impact factor: 2.584

Review 2.  Pharmacokinetics of inhaled nanotherapeutics for pulmonary delivery.

Authors:  Andrew M Shen; Tamara Minko
Journal:  J Control Release       Date:  2020-07-16       Impact factor: 9.776

3.  Liposomal dry powders as aerosols for pulmonary delivery of proteins.

Authors:  Dongmei Lu; Anthony J Hickey
Journal:  AAPS PharmSciTech       Date:  2005-12-21       Impact factor: 3.246

4.  Chapter 9 - Nanoliposomal dry powder formulations.

Authors:  Gaurang Patel; Mahavir Chougule; Mandip Singh; Ambikanandan Misra
Journal:  Methods Enzymol       Date:  2009       Impact factor: 1.600

Review 5.  Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation.

Authors:  Anil Kumar; Fei Chen; Anbu Mozhi; Xu Zhang; Yuanyuan Zhao; Xiangdong Xue; Yanli Hao; Xiaoning Zhang; Paul C Wang; Xing-Jie Liang
Journal:  Nanoscale       Date:  2013-09-21       Impact factor: 7.790

6.  Development of spray dried liposomal dry powder inhaler of Dapsone.

Authors:  Mahavir Chougule; Bijay Padhi; Ambikanandan Misra
Journal:  AAPS PharmSciTech       Date:  2008-01-09       Impact factor: 3.246

Review 7.  Nanomedicine in pulmonary delivery.

Authors:  Heidi M Mansour; Yun-Seok Rhee; Xiao Wu
Journal:  Int J Nanomedicine       Date:  2009-12-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.